Published in Clin Exp Immunol on December 01, 2004
Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med (2006) 2.11
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol (2008) 1.70
Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol (2013) 1.64
The alternative complement pathway revisited. J Cell Mol Med (2008) 1.62
Complement Factor B Production in Renal Tubular Cells and Its Role in Sodium Transporter Expression During Polymicrobial Sepsis. Crit Care Med (2016) 1.39
Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood (2007) 1.39
Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun (2008) 1.39
Oxidative stress and the regulation of complement activation in human glaucoma. Invest Ophthalmol Vis Sci (2010) 1.21
A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J Immunol (2009) 1.16
Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J Immunol (2014) 1.15
Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J (2015) 1.12
Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol (2013) 1.07
New concepts of complement in allorecognition and graft rejection. Cell Immunol (2007) 1.02
Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv Drug Deliv Rev (2011) 1.01
Inhibiting alternative pathway complement activation by targeting the factor D exosite. J Biol Chem (2012) 1.01
The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol Immunol (2011) 0.98
Polyglycolic acid-induced inflammation: role of hydrolysis and resulting complement activation. Tissue Eng (2006) 0.97
Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro. Clin Exp Immunol (2009) 0.97
Complement in disease: a defence system turning offensive. Nat Rev Nephrol (2016) 0.97
Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. J Ocul Pharmacol Ther (2012) 0.96
Diversity in the C3b [corrected] contact residues and tertiary structures of the staphylococcal complement inhibitor (SCIN) protein family. J Biol Chem (2011) 0.96
Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J Immunol (2011) 0.96
Therapeutic control of complement activation at the level of the central component C3. Immunobiology (2015) 0.94
Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology (2012) 0.93
Native properdin binds to Chlamydia pneumoniae and promotes complement activation. Infect Immun (2010) 0.91
Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus. Immunol Res (2013) 0.90
The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase. J Immunol (2014) 0.88
Alternative complement pathway deficiency ameliorates chronic smoke-induced functional and morphological ocular injury. PLoS One (2013) 0.88
Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions. Clin Exp Immunol (2006) 0.88
Molecular basis for complement recognition and inhibition determined by crystallographic studies of the staphylococcal complement inhibitor (SCIN) bound to C3c and C3b. J Mol Biol (2010) 0.88
The role of properdin in zymosan- and Escherichia coli-induced complement activation. J Immunol (2012) 0.87
Complement and Antibody-mediated Enhancement of Red Blood Cell Invasion and Growth of Malaria Parasites. EBioMedicine (2016) 0.86
Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert Rev Clin Immunol (2008) 0.86
Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology (2011) 0.85
Inhibition of complement activation on a model biomaterial surface by streptococcal M protein-derived peptides. Biomaterials (2009) 0.85
Properdin: a tightly regulated critical inflammatory modulator. Immunol Rev (2016) 0.85
Complement in the Homeostatic and Ischemic Brain. Front Immunol (2015) 0.83
Elevated properdin and enhanced complement activation in first-degree relatives of South Asian subjects with type 2 diabetes. Diabetes Care (2012) 0.82
Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci (2015) 0.81
Complement alternative pathway activation in the autologous phase of nephrotoxic serum nephritis. Am J Physiol Renal Physiol (2012) 0.81
A structurally dynamic N-terminal helix is a key functional determinant in staphylococcal complement inhibitor (SCIN) proteins. J Biol Chem (2012) 0.81
Hijacking Complement Regulatory Proteins for Bacterial Immune Evasion. Front Microbiol (2016) 0.80
From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology (2016) 0.80
Complement activation: an emerging player in the pathogenesis of cardiovascular disease. Scientifica (Cairo) (2012) 0.80
Bead arrays for antibody and complement profiling reveal joint contribution of antibody isotypes to C3 deposition. PLoS One (2014) 0.80
c-Jun and c-Fos regulate the complement factor H promoter in murine astrocytes. Mol Immunol (2011) 0.79
Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense. Immunol Rev (2016) 0.78
Ovariectomy and subsequent treatment with estrogen receptor agonists tune the innate immune system of the hippocampus in middle-aged female rats. PLoS One (2014) 0.78
Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy. Front Immunol (2016) 0.77
Identification of peptidic inhibitors of the alternative complement pathway based on Staphylococcus aureus SCIN proteins. Mol Immunol (2015) 0.77
Human Endothelial Cell Activation by Escherichia coli and Staphylococcus aureus Is Mediated by TNF and IL-1β Secondarily to Activation of C5 and CD14 in Whole Blood. J Immunol (2016) 0.76
Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation. Matrix Biol (2016) 0.76
Properdin binding to complement activating surfaces depends on initial C3b deposition. Proc Natl Acad Sci U S A (2017) 0.76
Complement activation and cytokine response by BioProtein, a bacterial single cell protein. Clin Exp Immunol (2007) 0.75
Biological characterization of compounds from Rhinella schneideri poison that act on the complement system. J Venom Anim Toxins Incl Trop Dis (2015) 0.75
Alternative Pathway Inhibition by Exogenous Factor H Fails to Attenuate Inflammation and Vascular Leakage in Experimental Pneumococcal Sepsis in Mice. PLoS One (2016) 0.75
Improved ex vivo blood compatibility of central venous catheter with noble metal alloy coating. J Biomed Mater Res B Appl Biomater (2015) 0.75
THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET. Retina (2016) 0.75
Complement. First of two parts. N Engl J Med (2001) 11.16
Arthritis critically dependent on innate immune system players. Immunity (2002) 5.31
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science (1990) 4.67
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood (2002) 2.62
The dark side of C5a in sepsis. Nat Rev Immunol (2004) 2.46
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest (2003) 2.39
Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A (2004) 2.30
Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection. N Engl J Med (1980) 2.07
Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol (1985) 2.06
Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol (2000) 1.55
The role of antibody in the activation of the alternative complement pathway. Springer Semin Immunopathol (1983) 1.55
Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol (2003) 1.49
Functional characterization of the lectin pathway of complement in human serum. Mol Immunol (2003) 1.48
Complement in inflammatory tissue damage and disease. Trends Immunol (2002) 1.43
Complement factor D, a novel serine protease. Protein Sci (1996) 1.33
Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol (1988) 1.15
Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int (2004) 1.15
Formation of high-affinity C5 convertases of the alternative pathway of complement. J Immunol (2001) 1.12
Ischaemia-reperfusion is an event triggered by immune complexes and complement. Br J Surg (2003) 1.12
Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass. Ann Thorac Surg (2002) 1.04
Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J Thorac Cardiovasc Surg (2001) 1.03
Formation of high affinity C5 convertase of the classical pathway of complement. J Biol Chem (2003) 1.02
Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Mol Immunol (2000) 1.02
Regulation of complement. Scand J Immunol (1988) 0.99
The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J Infect Dis (1996) 0.98
Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b. J Immunol (1989) 0.93
Complement system on the attack in autoimmunity. J Clin Invest (2003) 0.86
Production of monoclonal antibodies against the human anaphylatoxin C5a des Arg and their application in the neoepitope-specific sandwich-ELISA for the quantification of C5a des Arg in plasma. J Immunol Methods (1992) 0.86
The mechanism of activation of the alternative pathway of complement by cell-bound C4b. Mol Immunol (1990) 0.86
Binding of polymeric IgG to fibronectin in extracellular matrices: an in vitro paradigm for immune-complex deposition. Mol Immunol (2002) 0.83
Production of thromboxane A2 and prostaglandin i2 affected by interaction of heat aggregated IgG, endothelial cells, and platelets in lupus nephritis. J Rheumatol (2002) 0.79
Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol (1995) 2.22
Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol (1985) 2.06
The Shatin community mental health survey in Hong Kong. II. Major findings. Arch Gen Psychiatry (1993) 1.99
Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence. Gastroenterology (1989) 1.93
Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun (1999) 1.87
B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis. Infect Immun (1998) 1.86
Inversin, a novel gene in the vertebrate left-right axis pathway, is partially deleted in the inv mouse. Nat Genet (1998) 1.83
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol (1985) 1.72
Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J (2009) 1.62
Interleukin 2-induced tyrosine phosphorylation. Interleukin 2 receptor beta is tyrosine phosphorylated. J Biol Chem (1990) 1.58
Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest (1995) 1.57
Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology (1990) 1.53
Extracorporeal membrane oxygenation using a centrifugal pump and a servo regulator to prevent negative inlet pressure. Ann Thorac Surg (1997) 1.50
High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes. Ann Thorac Surg (1995) 1.48
Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro. J Thorac Cardiovasc Surg (1989) 1.45
Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis (1989) 1.44
Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol (2009) 1.37
Systemic meningococcal disease: a model infection to study acute endotoxinemia in man. Prog Clin Biol Res (1988) 1.30
Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut (1997) 1.27
Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes. Clin Exp Immunol (1988) 1.25
Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum (1986) 1.20
The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A (2008) 1.20
Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol (2004) 1.16
Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol (1988) 1.15
Differences in complement activation between complement-resistant and complement-sensitive Moraxella (Branhamella) catarrhalis strains occur at the level of membrane attack complex formation. Infect Immun (1994) 1.10
Persistent antinuclear antibodies in children without identifiable inflammatory rheumatic or autoimmune disease. Pediatrics (1992) 1.10
Acute phase haemolysis in chronic cold agglutinin disease. Scand J Immunol (2001) 1.10
Growth, compatible solute and salt accumulation of five mycorrhizal fungal species grown over a range of NaCl concentrations. Mycorrhiza (2005) 1.10
Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex. J Biol Chem (1992) 1.08
Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Pathol (1993) 1.06
Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. Gut (1992) 1.04
Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol (1995) 1.03
Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Clin Exp Immunol (1986) 1.01
Cultural brokering in community health. Can Nurse (1999) 1.01
Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. Circulation (2001) 1.01
Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex. Complement (1985) 1.00
Parameter estimation and confidence intervals for Xe-CT ventilation studies: a Monte Carlo approach. J Appl Physiol (1985) (1998) 1.00
Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. J Thorac Cardiovasc Surg (1999) 0.99
Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c. Scand J Immunol (1988) 0.98
The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J Infect Dis (1996) 0.98
Complement activation in synovial fluid and tissue from patients with juvenile rheumatoid arthritis. Arthritis Rheum (1986) 0.98
Complement activation by Pseudomonas aeruginosa biofilms. Microb Pathog (1993) 0.98
Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg (1994) 0.97
Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation (1999) 0.97
Biocompatibility of white cell filters as evaluated by complement activation. Transfusion (1992) 0.97
Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes. Mol Pharmacol (1995) 0.96
Reactivity of antinuclear antibodies with histones and other antigens in juvenile rheumatoid arthritis. Arthritis Rheum (1989) 0.95
Complement activation during major operations with or without cardiopulmonary bypass. J Thorac Cardiovasc Surg (1987) 0.95
IgG subclass distribution and complement activation ability of autoantibodies to neutrophil cytoplasmic antigens (ANCA). Clin Immunol Immunopathol (1994) 0.94
Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol (1996) 0.94
Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol (1996) 0.94
C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin Pharmacother (2001) 0.94
Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med (1990) 0.93
Terminal complement complex (TCC) and S-protein (vitronectin) on follicular dendritic cells in human lymphoid tissues. Immunology (1988) 0.93
Increased systemic activation of neutrophils but not complement in preeclampsia. Obstet Gynecol (2001) 0.92
C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model. Immunopharmacology (1999) 0.92
Quantification of the C3d split products of human complement by a sensitive enzyme-linked immunosorbent assay. Scand J Immunol (1985) 0.92
Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. Clin Exp Immunol (2005) 0.91
Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae. Clin Exp Immunol (1990) 0.91
Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor. Proc Natl Acad Sci U S A (1986) 0.91
Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. J Intern Med (1996) 0.91
Complement activation in injured patients occurs immediately and is dependent on the severity of the trauma. Injury (1998) 0.91
In situ deposition of complement in human acute brain ischaemia. Scand J Immunol (2009) 0.91
Detection and quantification of the terminal C5b-9 complex of human complement by a sensitive enzyme-linked immunosorbent assay. Scand J Immunol (1984) 0.90
Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg (1997) 0.90
On the blood compatibility of end-point immobilized heparin. J Biomater Sci Polym Ed (2000) 0.90
Both plasma- and leukocyte-associated C5a are essential for assessment of C5a generation in vivo. Ann Thorac Surg (1997) 0.89
A novel enzyme immunoassay for plasma thrombospondin. Comparison with beta-thromboglobulin as platelet activation marker in vitro and in vivo. Thromb Res (2000) 0.89
Transcriptional and post-transcriptional regulation of complement factor I (CFI) gene expression in Hep G2 cells by interleukin-6. Biochim Biophys Acta (1998) 0.89
Complement activation and complement-dependent inflammation by Neisseria meningitidis are independent of lipopolysaccharide. Infect Immun (2004) 0.89
Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility. Ann Thorac Surg (1996) 0.89
Budesonide inhibits T cell-initiated epithelial pathophysiology in an in vitro model of inflammation. J Pharmacol Exp Ther (1996) 0.88
Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions. Clin Exp Immunol (2006) 0.88
Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response. Perfusion (2010) 0.88
C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res (1994) 0.88
Terminal complement complexes and anaphylatoxins in septic and ischemic patients. Arch Surg (1988) 0.88
Synthesis of 4R- and 4S-tritium labeled NADPH for the determination of the coenzyme stereospecificity of NADPH: protochlorophyllide oxidoreductase. Biochem Biophys Res Commun (1987) 0.88
Differential effect of inhibiting MD-2 and CD14 on LPS- versus whole E. coli bacteria-induced cytokine responses in human blood. Adv Exp Med Biol (2012) 0.88
Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg (1992) 0.87
Increased interleukin-1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. J Intern Med (2012) 0.87
Changes in serum levels of E-selectin correlate to improved glycaemic control and reduced obesity in subjects with the metabolic syndrome. Scand J Clin Lab Invest (2005) 0.87
Body composition and plasma levels of inflammatory biomarkers in COPD. Eur Respir J (2010) 0.87
Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor Compstatin. Transplant Proc (1999) 0.87
New biomarkers in an acute model of live Escherichia coli-induced sepsis in pigs. Scand J Immunol (2008) 0.86
Methylene blue reduces pulmonary oedema and cyclo-oxygenase products in endotoxaemic sheep. Eur Respir J (2002) 0.86
Glomerular monocyte/macrophage influx correlates strongly with complement activation in 1-week protocol kidney allograft biopsies. Clin Nephrol (2004) 0.86
Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. J Thorac Cardiovasc Surg (1995) 0.86
Complement activation by neutrophil granulocytes. Scand J Immunol (2008) 0.85
Inflammatory response induced by candidate biomaterials of an implantable microfabricated sensor. J Biomed Mater Res A (2012) 0.85
The inflammatory response following treatment of abdominal aortic aneurysms: a comparison between open surgery and endovascular repair. Eur J Vasc Endovasc Surg (2000) 0.85
Cross-reaction between mammalian cell entry (Mce) proteins of Mycobacterium tuberculosis. Scand J Immunol (2002) 0.85
C3 is activated in hereditary angioedema, and C1/C1-inhibitor complexes rise during physical stress in untreated patients. Scand J Immunol (1995) 0.85
S-protein is synthesized by human monocytes and macrophages in vitro. Scand J Immunol (1989) 0.85
Transmembrane signalling by interleukin 2. Biochem Soc Trans (1991) 0.85
Activation of the third component of complement (C3) detected by a monoclonal anti-C3'g' neoantigen antibody in a one-step enzyme immunoassay. J Immunol Methods (1987) 0.85
MPB70 and MPB83 as indicators of protein localization in mycobacterial cells. Infect Immun (1998) 0.85
The effects of selective complement and CD14 inhibition on the E. coli-induced tissue factor mRNA upregulation, monocyte tissue factor expression, and tissue factor functional activity in human whole blood. Adv Exp Med Biol (2013) 0.85
Enhanced complement activation is part of the unfavourable cardiovascular risk profile in South Asians. Clin Exp Immunol (2009) 0.84